share_log

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Sees Significant Increase in Short Interest

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Sees Significant Increase in Short Interest

思维医学(MindMed)公司(纳斯达克代码：MNMD)在空头股数的销量大幅增长
Defense World ·  2022/10/03 02:21

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Rating) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 963,800 shares, a growth of 13.8% from the August 31st total of 846,700 shares. Based on an average daily trading volume, of 847,500 shares, the short-interest ratio is presently 1.1 days. Currently, 0.2% of the company's shares are short sold.

思维医学(纳斯达克代码：MNMD-GET Rating)在9月份的空头股数业务出现了大幅增长。截至9月15日，空头股数共有96.38万股，较8月31日的84.67万股增长13.8%。以日均成交量84.75万股计算，目前短息比为1.1天。目前，该公司0.2%的股票被卖空。

Mind Medicine (MindMed) Stock Up 1.7 %

Mind Medicine(MindMed)股价上涨1.7%

Shares of NASDAQ:MNMD opened at 3.50 on Monday. Mind Medicine has a 52-week low of 2.85 and a 52-week high of 44.10. The stock has a market cap of $99.70 million, a price-to-earnings ratio of -1.30 and a beta of 1.27. The business has a 50-day moving average price of 9.44 and a 200-day moving average price of 11.63.

周一，纳斯达克：MNMD的股价开盘报3.50美元。Mind Medicine的52周低点为2.85，52周高位为44.10。该股市值为9970万美元，市盈率为-1.30倍，贝塔系数为1.27。该业务的50日移动均线价格为9.44,200日移动均线价格为11.63。

Get
到达
Mind Medicine (MindMed)
精神医学(MindMed)
alerts:
警报：

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported -0.60 EPS for the quarter, beating analysts' consensus estimates of -0.75 by 0.15. As a group, equities analysts anticipate that Mind Medicine will post -2.51 EPS for the current fiscal year.

思维医学(MindMed)(纳斯达克代码：MNMD-GET Rating)最近一次公布季度收益数据是在8月11日(星期四)。该公司公布本季度每股收益为-0.60，超出分析师一致预期的-0.75-0.15。作为一个整体，股票分析师预计Mind Medicine本财年的每股收益将达到2.51欧元。

Institutional Trading of Mind Medicine (MindMed)

精神医学机构交易(MindMed)

A number of institutional investors and hedge funds have recently made changes to their positions in MNMD. Quantum Private Wealth LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $28,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $328,000. Laurion Capital Management LP acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $85,000. Millennium Management LLC boosted its stake in shares of Mind Medicine (MindMed) by 1,063.1% in the second quarter. Millennium Management LLC now owns 5,075,110 shares of the company's stock worth $3,249,000 after acquiring an additional 4,638,774 shares during the last quarter. Finally, LPL Financial LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $496,000. 5.10% of the stock is currently owned by hedge funds and other institutional investors.
一些机构投资者和对冲基金最近改变了他们在MNMD的头寸。量子私人财富有限责任公司在第二季度收购了MindMed的新股份，价值约28,000美元。Cubist Systems Strategy LLC在第二季度收购了MindMed(MindMed)的新股份，价值约328,000美元。Laurion Capital Management LP在第二季度收购了Mind Medicine(MindMed)价值约8.5万美元的新股份。千禧管理有限责任公司在第二季度将其在MindMed的股份增加了1063.1%。Millennium Management LLC在上个季度增持了4,638,774股后，现在拥有5,075,110股该公司股票，价值3,249,000美元。最后，LPL Financial LLC在第二季度收购了MindMed(MindMed)公司价值约49.6万美元的新股份。5.10%的股票目前由对冲基金和其他机构投资者持有。

Analyst Upgrades and Downgrades

分析师升级和下调评级

A number of research firms have weighed in on MNMD. HC Wainwright increased their target price on Mind Medicine (MindMed) to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, September 21st. Cantor Fitzgerald began coverage on Mind Medicine (MindMed) in a research report on Wednesday, August 10th. They set an "overweight" rating and a $45.00 price target on the stock. Finally, Oppenheimer increased their price target on Mind Medicine (MindMed) from $3.50 to $52.00 in a research report on Tuesday, August 30th.

一些研究公司已经对MNMD发表了看法。9月21日，周三，HC Wainwright在一份研究报告中将MindMed的目标价上调至75.00美元，并给出了该股的“买入”评级。坎托·菲茨杰拉德在8月10日星期三的一份研究报告中开始报道精神医学(MindMed)。他们为该股设定了“增持”评级和45.00美元的目标价。最后，在8月30日星期二的一份研究报告中，奥本海默将MindMed的目标价从3.50美元上调至52.00美元。

Mind Medicine (MindMed) Company Profile

Mind Medicine(MindMed)公司简介

(Get Rating)

(获取评级)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine(MindMed)Inc.是一家临床阶段的生物制药公司，开发新的产品来治疗与精神病学、成瘾、疼痛和神经学相关的大脑健康疾病。该公司开发了MM-120和MM-110，MM-120处于第二阶段，用于治疗广泛性焦虑症和注意力缺陷多动障碍，以及治疗慢性疼痛；MM-110是一种A3？4尼古丁胆碱能受体拮抗剂，已完成治疗阿片类药物戒断的第一阶段。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on Mind Medicine (MindMed) (MNMD)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • 免费获取StockNews.com关于精神医学的研究报告(MindMed)(MNMD)
  • 阿彻·丹尼尔斯·米德兰：49年增长的红利英雄
  • 全自动拖拉机会让迪尔成为农业领域的特斯拉吗？
  • 麦格纳国际是您的汽车和电动汽车一站式库存
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat：回顾一周9/26-9/30

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.

接受精神医学(MindMed)每日新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收有关Mind Medicine(MindMed)和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发